Alternatively, combining low concentrations of PRMT1 or PRMT5 inhibitors is well tolerated in mice and can synergically reduce growth and promote apoptosis in pancreatic cancer and DLBCL cancer cells (37). This evidence concerns the gene PRMT5 and pancreatic neoplasm.